Messmer-Blust, A.F., Balasubramanian, S., Gorbacheva, V.Y., Jeyaratnam, J.A. and Vestal, D.J. (2010) The Interferon-γ-Induced Murine Guanylate-Binding Protein-2 (mGBP-2) Inhibits Rac Activation during Cell Spreading on Fibronectin and after Platelet-Derived Growth Factor (PDGF) Treatment: Role for Phosphatidylinositol 3-Kinase. Molecular Biology of the Cell, 15, 2514-2528.
https://doi.org/10.1091/mbc.E09-04-0344

has been cited by the following article:

• TITLE: hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance

  AUTHORS: Suzan Wadi, Aaron R. Tipton, Jill A. Trendel, Sadik A. Khuder, Deborah J. Vestal

  KEYWORDS: Guanylate-Binding Protein, Paclitaxel, Ovarian Cancer, Drug Resistance, GTPase, TUBB3

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.13, December 8, 2016

  ABSTRACT: Ovarian cancer is the gynecological cancer with the poorest prognosis. One significant reason is the development of resistance to the chemotherapeutic drugs used in its treatment. The large GTPase, hGBP-1, has been implicated in paclitaxel resistance in ovarian cell lines. Forced expression of hGBP-1 in SKOV3 ovarian cancer cells protects them from paclitaxel-induced cell death. However, prior to this study, nothing was known about whether hGBP-1 was expressed in ovarian tumors and whether its expression correlated with paclitaxel resistance. hGBP-1 is expressed in 17% of ovarian tumors from patients that have not yet received treatment. However, at least 80% of the ovarian tumors that recurred after therapies that included a taxane, either paclitaxel or docetaxel, were positive for hGBP-1. In addition, hGBP-1 expression predicts a significantly shorter progression-free survival in ovarian cancers. Based on these studies, hGBP-1 could prove to be a potential biomarker for paclitaxel resistance in ovarian cancer.